These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 19726108)

  • 21. Low-dose aspirin for everyone?
    Johns Hopkins Med Lett Health After 50; 2002 Oct; 14(8):4-5. PubMed ID: 12425276
    [No Abstract]   [Full Text] [Related]  

  • 22. [Acetylsalicylic acid in patients with diabetes mellitus: can be used for secondary but not primary prevention of cardiovascular events].
    Klomp CM; ten Cate H; Stehouwer CD; Schaper NC
    Ned Tijdschr Geneeskd; 2009; 153():A109. PubMed ID: 19785798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aspirin therapy as primary prevention in hypertensive patients at Srinagarind hospital.
    Sawanyawisuth K; Limpawattana P; Bumrerraj S; Thongmee A; Kosakarn J; Choenrungroj T; Pradit P; Naranunn P; Punyamee S; Premgamone A
    J Med Assoc Thai; 2005 Dec; 88(12):1797-801. PubMed ID: 16518976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Aspirin in cardiovascular prevention: does the approach differ by gender?].
    Temizhan A
    Anadolu Kardiyol Derg; 2007 Dec; 7 Suppl 2():2-4. PubMed ID: 18160359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacologic interventions in primary prevention: lipid lowering drugs, aspirin, antiobesity drugs, and antihypertensive agents].
    Auer J; Berent R; Weber T; Porodko M; Mayr H; Maurer E; Eber B
    Wien Med Wochenschr; 2001; 151(1-2):13-7. PubMed ID: 11234591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Appropriate aspirin use for primary prevention of cardiovascular disease.
    Miser WF
    Am Fam Physician; 2011 Jun; 83(12):1380-6. PubMed ID: 21671538
    [No Abstract]   [Full Text] [Related]  

  • 27. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Primary prevention of cardiovascular disease].
    Gohlke H
    Dtsch Med Wochenschr; 2005 Jan; 130(1-2):38-43. PubMed ID: 15619173
    [No Abstract]   [Full Text] [Related]  

  • 29. Aspirin for the primary prevention of cardiovascular events: recommendations and rationale.
    U.S. Preventive Services Task Force
    Am Fam Physician; 2002 May; 65(10):2107-10. PubMed ID: 12046780
    [No Abstract]   [Full Text] [Related]  

  • 30. [Aspirin therapy for cardiovascular prevention in the diabetic patient: what have we learned from the evidence?].
    Legrand DA; Scheen AJ
    Rev Med Suisse; 2006 Aug; 2(76):1904-8. PubMed ID: 16972540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.
    Morimoto T; Fukui T; Lee TH; Matsui K
    Am J Med; 2004 Oct; 117(7):459-68. PubMed ID: 15464702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin.
    Bartolucci AA; Howard G
    Am J Cardiol; 2006 Sep; 98(6):746-50. PubMed ID: 16950176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The case against routine aspirin use for primary prevention in low-risk adults.
    Bailey AL; Smyth SS; Campbell CL
    Am Fam Physician; 2011 Jun; 83(12):1387-90. PubMed ID: 21671539
    [No Abstract]   [Full Text] [Related]  

  • 34. Use of antiplatelet therapy in a diabetic outpatient service of a large urban public hospital.
    Bruno A; Grassi G; Dani F; Degiovanni M; Maghenzani G; Pagano G
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):42-6. PubMed ID: 15871850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Laboratory-defined aspirin resistance and recurrent cardiovascular events.
    Fontana P; Reny JL
    Arch Intern Med; 2008 Mar; 168(5):549-50. PubMed ID: 18332305
    [No Abstract]   [Full Text] [Related]  

  • 36. [Prevention of cardiovascular events with antiplatelet drugs: aspirin (and others)?].
    Patrono C
    Minerva Cardioangiol; 1999 Nov; 47(11):389-90. PubMed ID: 10641409
    [No Abstract]   [Full Text] [Related]  

  • 37. Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V--Statins versus aspirin for primary prevention, and the winner is...?
    Moyad MA; Merrick GS
    Urol Nurs; 2007 Apr; 27(2):166-8. PubMed ID: 17494461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aspirin: its risks, benefits, and optimal use in preventing cardiovascular events.
    Park K; Bavry AA
    Cleve Clin J Med; 2013 May; 80(5):318-26. PubMed ID: 23636924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is aspirin resistance due to noncompliance?
    Dalen JE
    Arch Intern Med; 2008 Mar; 168(5):550; author reply 550. PubMed ID: 18332307
    [No Abstract]   [Full Text] [Related]  

  • 40. An update on aspirin in the primary prevention of cardiovascular disease.
    Eidelman RS; Hebert PR; Weisman SM; Hennekens CH
    Arch Intern Med; 2003 Sep; 163(17):2006-10. PubMed ID: 14504112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.